bluuebunny/crossref_metadata_2025_split huggingface dataset:
Congenital juvenile chronic myelogenous leukemia: Therapeutic trial with interferon alpha‐2
Authors: Hazani Anna , Barak Yigal , Berant Moshe , Bar‐Maor Adoniram 
Published: February 2007

AbstractA newborn with congenital juvenile chronic myelogenous leukemia (JCML) is described. The diagnosis was suggested by the characteristic clinical and hematologic presentation, and was confirmed by the results of in‐vitro cultures of the hematopoietic progenitors, which showed excessive proliferation of monocytic colonies, with and without the addition of exogenous granulocyte‐macrophage colony stimulating factor (GM‐CSF). Based on published in‐vitro response of JCML cells to alpha interferon‐2 (α IFN 2), we treated this child for 17 weeks with subcutaneous alpha interferon, 1,000,000 units per day. In contrast to previous in vitro results, treatment of this patient affected neither the clinical course of the disease, nor the in vitro growth of the peripheral blood‐derived monocytic colonies. © 1993 Wiley‐Liss, Inc.
Intracerebral recurrence of primary intrathoracic rhabdomyosarcoma
Authors: Micallef‐Eynaud Paul D. , Goulden Nicholas T. , Langdale‐Brown Barbara , Eden Tim B. , Steers James W. 
Published: February 2007

AbstractWe present two cases of intracerebral recurrence of primary intrathoracic rhabdomyosarcoma, occurring within 2 months of each other. Both had embryonal histological features. One (case 1) almost certainly arose within the lung adjacent to a developmental cyst; the intrathoracic site of origin of the other (case 2) was difficult to ascertain. Both were treated on SIOP MMT protocols. The intracerebral deposits became clinically apparent soon after completing chemotherapy. They were removed surgically and second‐line chemotherapy was given both systemically and intrathecally. Neither received radiotherapy. The disease recurred in both children whilst on therapy and they died as a consequence of raised intracranial pressure. © 1993 Wiley‐Liss, Inc.
Translocation t(11;19) (q23;p13) in a child with myelomonocytic leukemia following 2 years after chemotherapy for pneumoblastoma
Authors: Rialland Xavier , Pein François , Saint‐Andre Jean‐Paul , Flamant Françoise 
Published: February 2007

AbstractA child, who received successful chemotherapy for pneumoblastoma, developed a myelomonocytic leukemia with translocation t(11;19)(q23;p13) 2 years later. Although this leukemia did not present with features generally associated with therapy‐related leukemias, we think this hematologic disease to be secondary to previous chemotherapy. Involvement of chromosome 11q23 is common in acute leukemia and seems to be more significantly related to ANLL in young children (M4 and M5 FAB classification). However, our observation and previous reports suggest that this chromosomal abnormality might be more frequent in therapy‐related leukemias. The responsibility of etoposide and cisplatin may be discussed in such secondary malignancies. © 1993 Wiley‐Liss, Inc.
Leukemic blasts with markers of four cell lineages in Down's syndrome (“megakaryoblastic leukemia”)
Authors: Slørdahl Sofie H. , Smeland Erlend B. , Holte Harald , Grønn Morten , Lie Sverre O. , Seip Martin 
Published: February 2007

AbstractAmong 16 patients with Down's syndrome (DS) and acute leukemia admitted to our department during a ten year period, 6 were diagnosed as acute megakaryoblastic leukemia (AMkL). The diagnosis was based on clinical and hematologic criteria, confirmed in three patients with the use of monoclonal antibodies (MoAb) specific for megakaryocytic antigens. In these three, and in a fourth patient, the leukemic blasts were positive for other myeloid, lymphoid and erythroid markers in MoAb testing. We suggest that AMkL in DS is a mixed lineage leukemia with blasts presenting a variety of cell surface antigens, indicating origin from an early progenitor cell with the capability of megakaryocytic differentiation. Of the 6 patients with AMkL, 4 treated with standard AML protocols are in complete continuing remission (CCR) with observation periods from 57+ to 148+ months. © 1993 Wiley‐Liss, Inc.
Cytosine‐arabinoside, vincristine, and prednisolone in the treatment of children with disseminated langerhans cell histiocytosis with organ dysfunction: Experience at a single institution
Authors: Egeler R. Maarten , De Kraker Jan , Voǔte P. A. 
Published: February 2007

AbstractFifty‐two pediatric patients with Langerhans cell histiocytosis (LCH) were diagnosed at the Emma Kinderziekenhuis (EKZ) in Amsterdam over a 20‐year period. Eight patients with multiorgan involvement with organ dysfunction and ten patients with multiorgan involvement without organ dysfunction received chemotherapy containing cytosine‐arabinoside, vincristine, and prednisolone as part of their treatment. Five of the 8 patients (63%) with organ dysfunction and eight of the 10 (80%) without the organ dysfunction who needed chemotherapy because of the deteriorating of symptoms despite conventional therapy are presently in complete clinical remission. Two of those with organ dysfunction have died. Four of the total 18 patients developed diabetes insipidus either as an initial symptom or during the course of the disease. These results in both groups compare satisfactorily with other chemotherapeutic regimens, and since this combination is only mildly toxic, it has been well tolerated. Therefore we would recommend wider experience using this regimen in patients with widespread LCH with organ dysfunction as well as in patients with disseminated LCH in which chemotherapy proved to be necessary. © 1993 Wiley‐Liss, Inc.
Malignant germ cell tumours in two siblings
Authors: Blake Kathryn I. , Gerrard Mary P. 
Published: February 2007

AbstractFamilial germ cell tumours are well recognised in kinship with gonadal dysgenesis, but their occurrence in siblings with normal chromosomes is rare. We report two sisters who presented within a 4 month period with malignant ovarian germ cell tumours; one a dysgerminoma and the other a mixed tumour with marked choriocarcinomatous elements. Both children had a normal female constitutional karyotype and normal phenotype. © 1993 Wiley‐Liss, Inc.
Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma
Authors: Bruggers Carol S. , Friedman Henry S. , Fuller Gregory N. , Tien Robert D. , Marks Lawrence B. , Halperin Edward C. , Hockenberger Beverly , Oakes W. Jerry , Hoffman John M. 
Published: February 2007

AbstractProfound clinical deficits may be associated with insults to the brainstem, making management of patients with brainstem gliomas very complex. Small changes in the radiographic appearance of a brainstem tumor may be associated with significant clinical deterioration. Furthermore, both magnetic resonance imaging and computed tomography are frequently unable to differentiate between therapy‐related tissue reactions and progressive tumor. Two clinical scenarios particularly difficult to resolve include: (1) transient radiographic and clinical deterioration following hyperfractionated radiotherapy, and (2) clinical deterioration in a patient who has failed initial therapy, but has stable radiographic findings following a second therapy. We report a child with a pontine glioma whose tumor progression was demonstrated more convincingly with a 18F‐deoxyglucose positron emission scan than with magnetic resonance imaging. PET scans may be helpful in confirming that tumor progression is responsible for clinical deterioration in a patient whose MRI scans remain stable. © 1993 Wiley‐Liss, Inc.
Ten‐year survey of the intellectual deficits in children with acute lymphoblastic leukemia receiving chemoimmunotherapy
Authors: Kato Mitsuko , Azuma Eiichi , Ido Masaru , Ito Masahiro , Nii Ritsue , Higuchi Kazuo , Thara Toshiaki , Kamiya Hitoshi , Sakurai Minoru 
Published: February 2007

AbstractEffects of chemoimmunotherapy, including cranial irradiation for central nervous system (CNS)‐directed therapy, on children with acute lymphoblastic leukemia (ALL) were investigated. Fifty‐five children with ALL in continuous complete remission (<5 yr) and without evidence of current or past CNS diseases were evaluated in this retrospective study. Using standard measures of intelligence (IQ), we repeatedly (1–4 times/person; mean 2.1 times) evaluated IQ in the cohort of patients for the mean follow‐up time of 9.7 yr, ranging from 5.4 to 15.8 yr. Fifty‐five patients received the total number of 118 IQ testings and 40 patients received them more than twice. Patients were examined periodically at intervals of 1.4 to 10.0 yr (mean 4.8 yr) following diagnosis. Most of the published studies dealt with single IQ testing, and long‐term follow‐ups were not enough to assess the consequent IQ change. This report confirms and extends the previous findings: decreased IQ was related to age at diagnosis and irradiation (<5 yr of age at diagnosis), irradiation‐examination interval, and female sex. Further long‐term follow‐up study will be needed in these groups, since their IQs are still on the decline even after 10 yr of diagnosis. © 1993 Wiley‐Liss, Inc.
Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non‐Hodgkin's lymphoma: Cancer and leukemia group B study 8351
Authors: Rybak Mary Ellen , Anderson James , Kaplan Richard , Budman Daniel R. , Vinciguerra Vincent , Gottlieb Arlan J. 
Published: February 2007

AbstractA phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated for this report. The treatment regimen consisted of etoposide, 80 mg/m2 IV daily times 5 and cisplatin 20 mg/m2 IV daily times 5, repeated every 21 days. All patients had failed 1–3 prior chemotherapeutic regimens, had measurable disease, and had a performance status of 0–2. In the 51 evaluable patients, there were 4 complete responses (8%) and 12 partial responses (23%), for an overall response rate of 31% (95% Cl: 19%, 46%). In addition, 15 patients (29%) had some improvement in disease and 6 (12%) had stable disease. Failure‐free survival for the 51 eligible patients was 40% at 3 months, 23% at 6 months, and 15% at 1 year. Significant toxicity was observed with this regimen. Severe neutropenia occurred in 20 patients (39%), severe anemia in 8 patients (16%), and severe thrombocytopenia in 18 patients (35%). One patient died of infection. Severe neurotoxicity (1) and hemorrhage (3) were also seen.The etoposide, cisplatin combination is active in NHL; however, in this dose and schedule their combined activity is only minimally better than published reports of etoposide alone. Further studies of related combinations are under evaluation by the CALGB. © 1993 Wiley‐Liss, Inc.
Acute lymphoblastic leukemia in Noonan syndrome: Report of two cases
Authors: Piombo Margherita , Rosanda Cristina , Pasino Mirella , Marasini Maurizio , Cerruti Paola , Comelli Adele 
Published: February 2007

AbstractOnly two cases of Noonan Syndrome (NS) associated with tumor have previously been reported. The authors describe two new cases of NS with acute lymphoblastic leukemia (ALL), which were part of a series of 370 consecutive ALL untreated patients. © 1993 Wiley‐Liss, Inc.
Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia
Authors: Bührer Christoph , Hartmann Reinhard , Fengler Rüdiger , Dopfer Roland , Gadner Helmut , Gerein Valentin , Gobel Ulrich , Reiter Alfred , Ritter Jörg , Henze Günter 
Published: February 2007

AbstractThree hundred twenty‐six children with bone marrow (BM) relapse of non‐B acute lymphoblastic leukemia (ALL) were stratified according to the time of relapse in three consecutive multicenter trials—ALL‐REZ BFM 83, 85, and 87. Employing an intensive polychemotherapy regimen, extramedullary involvement appeared to be predictive of superior outcome in both strata as well as in the whole group (probability of 7‐year event free survival (EFS) 42% in combined vs. 15% in isolated BM relapse, P = 0.015). Children with combined BM relapse occurring later than 6 months after completion of front‐line therapy reached EFS estimates of 60%. We conclude that results of conventional poly‐chemotherapy with BFM relapse protocols are equivalent to those achieved by bone marrow transplantation in children with late combined BM relapse. © 1993 Wiley‐Liss, Inc.
Cisplatin‐resistant metastatic hepatoblastoma: Complete response to carboplatin, etoposide, and liver transplantation
Authors: Lockwood Liane , Heney David , Giles Geoffrey R. , Lewis Ian J. , Bailey Clifford C. 
Published: February 2007

AbstractA child with stage 4 hepatoblastoma failed to respond to treatment with cisplatin and adriamycin. She then showed a response to carboplatin with complete clearing of pulmonary metastases. Bilobar liver disease persisted, although significantly reduced in size. A liver transplant was subsequently performed and she remains in complete remission 36 months later. After the first course of carboplatin, there was a dramatic rise in alpha‐feto protein which then fell exponentially. Carboplatin warrants further study in hepatoblastoma. © 1993 Wiley‐Liss, Inc.
SIOP working committee on psychosocial issues in pediatric oncology
Authors: Masera Giuseppe , Spinetta John J. , D'Angio Giulio J. , Green Daniel M. , Marky Ildiko , Jankovic Momcilo , Karamoschoglou Loumidi D. , Mor Wolfgang , Jones Patricia Morris , Stocker Martina , Postma Agneta , Nesbit Mark E. , Schuler Dezso , Stevens Michael , Wilbur Jordan 
Published: February 2007

AbstractRecognizing the importance of psycho‐social issues in the care and cure of the child with cancer, the board of the International Society of Pediatric Oncology (SIOP) in 1991 constituted a Working Committee on Psychosocial Issues in Pediatric Oncology, with Giuseppe Masera as chair and John Spinetta as co‐chair. This committee met for the first time in Rhodes, Greece, in October 1991. The committee discussed various psychosocial issues and developed a document on Aims and Recommendations, summarizing the experiences of major centers. This document was approved by the SIOP board, which recommended diffusion of the document to the pediatric oncology community. © 1993 Wiley‐Liss, Inc.
Primitive malignant nonepithelial hepatic tumors in children
Authors: Babin‐Boilletot Annie , Flamant Françoise , Terrier‐Lacombe Marie‐José , Marsden H. Basil , van Unnik Adriaan , Deméocq François , Zucker Jean‐Michel , Voúte Paul A. , Otten Jacques , Behar Catherine , Valayer Jacques 
Published: February 2007

AbstractPrimary intrahepatic malignant nonepithelial tumors are very rare in children and account for 2% of all malignant mesenchymatous tumors under the age of 15 years. Clinical presentation, radiologic features, and histologic types are not unequivocal. The predominant role of surgery takes place either initially in small localized tumors or later, after initial reductive chemotherapy. In all cases, complete resection is the necessary but not sufficient condition for cure. Additional radiotherapy seems ineffective. High‐dose chemotherapy and/or liver transplantation can be proposed for resistant cases. The disease‐free survival rate is 37% at 2 years for the whole series. © 1993 Wiley‐Liss, Inc.
Carboplatin‐induced regression of an optic pathway tumor in a child with neurofibromatosis
Authors: Charrow Joel , Listernick Robert , Greenwald Mark J. , Das Lakshmi , Radkowski Mary Ann 
Published: February 2007

AbstractOptic pathway tumors are common in children with neurofibromatosis‐1 (NF‐1). The optimal management of these tumors is unknown, particularly when the optic chiasm and other brain structures are involved. We report the dramatic response to carboplatin in a 10‐year‐old girl with NF‐1 and a progressive optic pathway tumor. Tumor shrinkage was accompanied by striking improvement in visual fields, return of color discrimination, and marked improvement in visual acuity. No significant toxicity was observed. One year following completion of chemotherapy the glioma remains as small or smaller than it was at the conclusion of therapy, and there has been no deterioration of vision. Carboplatin is a promising agent for the treatment of optic pathway tumors in children with NF‐1. © 1993 Wiley‐Liss, Inc.
Non‐midline endodermal sinus tumor in the head and neck region: A case report
Authors: Kebudi Rejin , Ayan Inci , Darendeliler Emin , Agaoglu Leyla , Kunay Munir , Olgac Vakur , Bilge Nijad 
Published: February 2007

AbstractGerm cell tumors, in particular teratomas, are some of the most commonly found tumors in childhood. Six percent of all germ cell tumors are located in the head and neck region. Endodermal sinus tumors (yolk sactumors) of the head and neck, exclusive of the central nervous system, are rare. This study reports a 20‐month‐old girl with a mass of 5 × 5 cm on the left temporal area and with bone destruction on CT. The histopathological examination of the excised mass revealed an endodermal sinus tumor. The serum AFP and the LDH levels were elevated at diagnosis. The patient was treated by the BEP protocol (bleomycin, etoposide, and cisplatin), six cycles every three weeks. Partial response was attained after the first and complete response after the fourth cycle. The patient, who is being followed up, has been in remission for five months. © 1993 Wiley‐Liss, Inc.
Neurofibromatosis type I and malignancy: Review of 32 pediatric cases treated at a single institution
Authors: Shearer Patricia , Parham David , Kovnar Edward , Kun Larry , Rao Bhaskar , Lobe Thom , Pratt Charles 
Published: February 2007

AbstractThirty‐two cases of neurofibromatosis Type I (NF1) were identified among 6,678 pediatric cancer patients treated at St. Jude Children's Research Hospital over a 29‐year period. A total of 35 malignant neoplasms have been diagnosed in these patients. Two of three patients with second malignant neoplasms had colon cancer as the primary or second tumor. Of particular interest are two cases in which both NF1 and malignant peripheral nerve sheath tumors were present in multiple successive generations: a patient with colon cancer and non‐Hodgkin lymphoma who has a constitutional abnormality of the p53 gene, and a patient with acute lymphoblastic leukemia with the Philadelphia chromosome and other cytogenetic abnormalities, including the t(8;14). Outcome of patients in the largest subgroup, that of malignant peripheral nerve sheath tumors, was favorable only for those patients having resectable extremity lesions. In contrast, all patients with central nervous system tumors are surviving. These cases reflect the molecular and cytogenetic abnormalities that can be present in NF1 and the variety of tumors that may result in these patients. © 1994 Wiley‐Liss, Inc.
Therapy of disseminated malignant melanoma with recombinant α 2b‐interferon and piroxicam: Clinical results with a report of an unusual response‐associated feature (Vitiligo) and unusual toxicity (diffuse pulmonary interstitial fibrosis)
Authors: Harris Jules , Bines Steven , Das Gupta Tapas 
Published: February 2007

AbstractFifteen patients with disseminated malignant melanoma were treated with recombinant a 2b‐interferon (20 mU/m2 intravenously 5 days per week for 4 weeks and then 10 mU/m2 subcutaneously tiw) and piroxicam (10 mg a day orally for 10 days prior to beginning interferon and daily thereafter). Two complete responses of soft tissue disease and stabilization of disease in two other patients were obtained. One complete response was associated with the development of vitiligo. One patient who had entered complete remission was removed from the study because of diffuse pulmonary interstitial fibrosis, believed due to therapy. The combination of α 2b‐interferon and piroxicam offers no clinical advantage over the use of α 2b‐interferon alone. © 1994 Wiley‐Liss, Inc.
Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine
Authors: Leblanc Thierry , Deméocq François , Leverger Guy , Baruchel André , Lemerle Sophie , Vannier Jean Pierre , Nelken Brigitte , Guillot Thierry , Schaison Gérard 
Published: February 2007

AbstractBisantrene is an anthracene derivative which has demonstrated activity in acute myeloblastic leukemia (AML) and in lymphoma. The present study was designed to assess the reinduction rate and toxicity of bisantrene (250 mg/m2/d × 5) associated with aracytine (1000 mg/m2 twice a day × 5) in refractory and relapsed acute childhood leukemia. Patients who relapsed after bone marrow transplantation were eligible. Twenty‐six children were included. Diagnoses were as follows: 13 AML, 9 acute lymphoblastic leukemia (ALL), and 4 undifferentiated leukemia (AUL). All patients had been very highly pretreated, especially with anthracyclines, and most of them were of poor prognosis. The overall response rate was 46% with a 95% confidence interval ranging from 27‐65%. According to diagnosis, complete remission (CR) rates are: AML: 5/13, ALL: 5/9, and AUL: 2/4. Four children died, three from infection and one from acute lysis syndrome. The major toxicity was infection with grade 3 and 4 episodes occurring in 42% of patients. No significant cardiac toxicity was noted. Hepatic and renal toxicity were limited and transient. Bisantrene in association with aracytine is effective in both AML and ALL of childhood. Bisantrene should be evaluated with a five‐day schedule in other pediatric malignancies. In children with acute leukemia previously treated with high dose aracytine, new combination regimen is warranted. © 1994 Wiley‐Liss, inc.
Arteriovenous malformation mimicking recurrent medulloblastoma
Authors: Moghrabi Albert , Friedman Henry S. , McLendon Roger , Pa‐C Beverly Hockenberger , Tien Robert D. , Halperin Edward C. , Oakes W. Jerry 
Published: February 2007

AbstractMagnetic resonance imaging (MRI) is becoming the method of choice for evaluation of central nervous system tumors. However, the sensitivity of this modality raises concern that new lesions in patients previously diagnosed with a brain tumor may not necessarily represent recurrent disease. We report a patient previously treated with surgery, radiotherapy, and chemotherapy for a medulloblastoma who developed a new lesion in the floor of the fourth ventricle. Histologic review following excision revealed an arteriovenous malformation. © 1994 Wiley‐Liss, inc.
Anaplastic large cell lymphoma of true histiocytic origin in an infant: Unusual clinical, hematological, and cytogenetic features
Authors: Ferster Alina , Corazza Francis , Heimann Pierre , Dehou Marie‐Françoise , De Busscher Chantal , Devalck Christine , Sariban Eric , Vamos Esther 
Published: February 2007

AbstractWe report here the case of a 7‐month‐old boy who developed anaplastic large cell lymphoma of true histiocytic origin or malignant histiocytosis, with fever, bone and bone marrow infiltration. Usual clinical features were absent. The neoplastic nature of the disease was supported by the presence of clonal chromosomal abnormalities [t(6;8)(p23;P21),der(8)del(8)(q11aq13), der(22) t(11;22) (q13;13)]. Neither B nor T lineage could be demonstrated here. Morphology, ultrastructural analysis, surface antigens expression, and cytogenetics were more specific for the monocyte‐macrophage lineage.